615731650	615731650	CD	B-NP	O
|	|	NN	I-NP	O
AH	AH	NN	I-NP	O
|	|	NN	I-NP	O
09399642	09399642	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
451322	451322	CD	B-NP	O
|	|	CC	I-NP	O
5/11/1990	5/11/1990	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Summary	Summary	NNP	I-NP	O
|	|	NNP	I-NP	O
Unsigned	Unsigned	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
7/24/1990	7/24/1990	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
9/24/1990	9/24/1990	CD	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
APLASTIC	APLASTIC	NN	I-NP	O
ANEMIA	ANEMIA	NN	I-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
ANTITHROMBOCYTE	ANTITHROMBOCYTE	NNP	I-NP	B-protein
GLOBULIN	GLOBULIN	NNP	I-NP	I-protein
THERAPY	THERAPY	NNP	I-NP	O
FOR	FOR	IN	B-NP	O
10	10	CD	I-NP	O
DAYS	DAYS	NN	I-NP	O
.	.	.	O	O

3	3	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
OTITIS	OTITIS	NNP	I-NP	O
MEDIA	MEDIA	NNP	I-NP	O
.	.	.	O	O

4	4	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
SERUM	SERUM	NNP	I-NP	O
SICKNESS	SICKNESS	NNP	I-NP	O
.	.	.	O	O

5	5	CD	B-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
HIV	HIV	NN	I-NP	O
NEGATIVE	NEGATIVE	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
26-year-old	26-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
who	who	WP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
15	15	CD	I-NP	O
year	year	NN	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
aplastic	aplastic	JJ	B-NP	O
anemia	anemia	NN	I-NP	O
without	without	IN	B-PP	O
known	known	JJ	B-NP	O
cause	cause	NN	I-NP	O
and	and	CC	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
transfusions	transfusion	NNS	I-NP	O
admitted	admit	VBN	B-VP	O
for	for	IN	B-PP	O
ATG	ATG	NN	B-NP	O
trial	trial	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
diagnosed	diagnose	VBN	I-VP	O
with	with	IN	B-PP	O
aplastic	aplastic	JJ	B-NP	O
anemia	anemia	NN	I-NP	O
in	in	IN	B-PP	O
1976	1976	CD	B-NP	O
at	at	IN	B-PP	O
Phhealt	Phhealt	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
when	when	WRB	B-ADVP	O
admitted	admit	VBN	B-VP	O
for	for	IN	B-PP	O
epistaxis	epistaxis	NN	B-NP	O
,	,	,	O	O
unknown	unknown	JJ	B-NP	O
workup	workup	NN	I-NP	O
,	,	,	O	O
unknown	unknown	JJ	B-NP	O
cause	cause	NN	I-NP	O
.	.	.	O	O

Denies	Deny	NNS	B-NP	O
drug	drug	NN	I-NP	O
or	or	CC	O	O
chemical	chemical	JJ	B-NP	O
exposure	exposure	NN	I-NP	O
or	or	CC	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Hct	Hct	NN	B-NP	B-protein
30	30	CD	I-NP	I-protein
,	,	,	O	O
platelets	platelet	VBZ	B-VP	O
100	100	CD	B-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
,	,	,	O	O
white	white	JJ	B-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
ran	run	VBD	B-VP	O
at	at	IN	B-PP	O
around	around	IN	B-NP	O
4000	4000	CD	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
diagnosed	diagnose	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
aplastic	aplastic	JJ	I-NP	O
anemia	anemia	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
treatment	treatment	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
in	in	IN	B-PP	O
past	past	NN	B-NP	O
has	have	VBZ	B-VP	O
declined	decline	VBN	I-VP	O
further	further	JJ	B-NP	O
treatment	treatment	NN	I-NP	O
and	and	CC	O	O
often	often	RB	B-VP	O
was	be	VBD	I-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
non-compliant	non-compliant	JJ	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

Evidently	Evidently	RB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
HLA	HLA	NN	I-NP	O
identical	identical	JJ	I-NP	O
brother	brother	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
out	out	RP	B-PRT	O
during	during	IN	B-PP	O
earlier	early	JJR	B-NP	O
diagnosis	diagnosis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
brief	brief	JJ	B-NP	O
trial	trial	NN	I-NP	O
of	of	IN	B-PP	O
androgen	androgen	NN	B-NP	O
treatment	treatment	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
14	14	CD	B-NP	O
of	of	IN	B-PP	O
September	September	NNP	B-NP	O
her	her	PRP$	B-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
2.5	2.5	CD	B-NP	O
,	,	,	O	O
Hct	Hct	NN	B-NP	B-protein
19.6	19.6	CD	I-NP	I-protein
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
5000	5000	CD	B-NP	O
,	,	,	O	O
MCV	MCV	NN	B-NP	B-DNA
96	96	CD	I-NP	I-DNA
,	,	,	O	O
polys	poly	NNS	B-NP	O
10	10	CD	B-NP	O
,	,	,	O	O
lymphs	lymph	NNS	B-NP	O
87	87	CD	B-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
similar	similar	JJ	B-ADJP	O
to	to	TO	B-PP	O
baseline	baseline	NN	B-NP	O
but	but	CC	I-NP	O
platelets	platelet	NNS	I-NP	B-cell_type
are	be	VBP	B-VP	O
usually	usually	RB	B-ADVP	O
more	more	JJR	B-NP	O
around	around	IN	I-NP	O
10	10	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
q	q	NN	B-NP	O
three	three	CD	I-NP	O
week	week	NN	I-NP	O
transfusions	transfusion	NNS	I-NP	O
without	without	IN	B-PP	O
platelets	platelet	NNS	B-NP	B-cell_type
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
now	now	RB	I-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
ATGAM	ATGAM	NN	B-NP	O
therapy	therapy	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
more	more	RBR	B-ADJP	O
compliant	compliant	JJ	I-ADJP	O
with	with	IN	B-PP	O
transfusions	transfusion	NNS	B-NP	O
recently	recently	RB	B-ADVP	O
than	than	IN	B-PP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
requiring	require	VBG	I-VP	O
them	them	PRP	B-NP	O
more	more	RBR	B-ADVP	O
but	but	CC	O	O
this	this	DT	B-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
increased	increase	VBN	I-NP	O
compliance	compliance	NN	I-NP	O
and	and	CC	O	O
increased	increase	VBN	B-NP	O
activity	activity	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
usual	usual	JJ	I-NP	O
state	state	NN	I-NP	O
of	of	IN	B-PP	O
health	health	NN	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
cough	cough	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
smoking	smoking	NN	B-NP	O
and	and	CC	O	O
white	white	JJ	B-NP	O
sputum	sputum	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
headache	headache	NN	I-NP	O
,	,	,	O	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
vomiting	vomiting	NN	B-NP	O
,	,	,	O	O
diarrhea	diarrhea	NN	B-NP	O
,	,	,	O	O
fever	fever	NN	B-NP	O
,	,	,	O	O
chills	chill	NNS	B-NP	O
,	,	,	O	O
night	night	NN	B-NP	O
sweats	sweat	NNS	I-NP	O
,	,	,	O	O
dysuria	dysuria	NN	B-NP	O
,	,	,	O	O
urine	urine	NN	B-NP	O
or	or	CC	O	O
bowel	bowel	NN	B-NP	O
movement	movement	NN	I-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
cauterization	cauterization	NN	B-NP	O
for	for	IN	B-PP	O
epistaxis	epistaxis	NN	B-NP	O
.	.	.	O	O

Positive	Positive	JJ	B-NP	O
easy	easy	JJ	I-NP	O
bruisability	bruisability	NN	I-NP	O
,	,	,	O	O
gum	gum	NN	B-NP	O
bleed	bleed	NN	I-NP	O
without	without	IN	B-PP	O
trauma	trauma	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
last	last	JJ	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
epistaxis	epistaxis	NN	B-NP	O
on	on	IN	B-PP	O
17	17	CD	B-NP	O
of	of	IN	B-PP	O
September	September	NNP	B-NP	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
four	four	CD	B-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
which	which	WDT	B-NP	O
lasted	last	VBD	B-VP	O
45	45	CD	B-NP	O
to	to	TO	B-PP	O
50	50	CD	B-NP	O
minutes	minute	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
last	last	JJ	I-NP	O
menstrual	menstrual	JJ	I-NP	O
period	period	NN	I-NP	O
was	be	VBD	B-VP	O
the	the	DT	B-NP	O
third	third	JJ	I-NP	O
week	week	NN	I-NP	O
of	of	IN	B-PP	O
10	10	CD	B-NP	O
of	of	IN	B-PP	O
October	October	NNP	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
menometrorrhagia	menometrorrhagia	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
nausea	nausea	NN	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
menses	mens	NNS	I-NP	O
.	.	.	O	O

CURRENT	CURRENT	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Last	Last	JJ	B-NP	O
month	month	NN	I-NP	O
she	she	PRP	B-NP	O
stopped	stop	VBD	B-VP	O
birth	birth	NN	B-NP	O
control	control	NN	I-NP	O
pill	pill	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
non-compliance	non-compliance	JJ	B-ADJP	O
and	and	CC	O	O
uses	use	VBZ	B-VP	O
condoms	condom	NNS	B-NP	O
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Notable	Notable	NNP	B-NP	O
for	for	IN	B-PP	O
Gravida	Gravida	NNP	B-NP	O
VI	VI	NNP	I-NP	O
Para	Para	NNP	I-NP	O
III	III	NNP	I-NP	O
AB	AB	NN	I-NP	O
III	III	CD	I-NP	O
,	,	,	O	O
twins	twin	VBZ	B-VP	O
times	time	NNS	B-NP	O
one	one	CD	B-NP	O
.	.	.	O	O

Last	Last	JJ	B-NP	O
pregnancy	pregnancy	NN	I-NP	O
in	in	IN	B-PP	O
8	8	CD	B-NP	O
of	of	IN	B-PP	O
September	September	NNP	B-NP	O
,	,	,	O	O
discontinued	discontinue	VBD	B-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
birth	birth	NN	B-NP	O
abnormality	abnormality	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
15	15	CD	I-NP	O
year	year	NN	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
aplastic	aplastic	JJ	B-NP	O
anemia	anemia	NN	I-NP	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
previously	previously	RB	I-VP	O
tested	test	VBN	I-VP	O
HIV	HIV	NN	B-NP	O
and	and	CC	I-NP	O
HPV	HPV	NN	I-NP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
cocaine	cocaine	NN	B-NP	O
use	use	NN	I-NP	O
,	,	,	O	O
smoking	smoking	NN	B-NP	O
,	,	,	O	O
approximately	approximately	RB	B-ADVP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
;	;	:	O	O
alcohol	alcohol	NN	B-NP	O
one	one	CD	B-NP	O
pint	pint	NN	I-NP	O
of	of	IN	B-PP	O
hard	hard	JJ	B-NP	O
liquor	liquor	NN	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
;	;	:	O	O
smoking	smoke	VBG	B-VP	O
one	one	CD	B-NP	O
half	half	NN	I-NP	O
to	to	TO	B-PP	O
one	one	CD	B-NP	O
pack	pack	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
lives	live	VBZ	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
father	father	NN	I-NP	O
,	,	,	O	O
uncle	uncle	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
three	three	CD	B-NP	O
children	child	NNS	I-NP	O
and	and	CC	O	O
occasionally	occasionally	RB	B-VP	O
works	work	VBZ	I-VP	O
at	at	IN	B-PP	O
Do	Do	NNP	B-NP	O
Rochealesall	Rochealesall	NNP	I-NP	O
Wia	Wia	NNP	I-NP	O
PHYSICAL	PHYSICAL	NNP	I-NP	O
EXAMINATION	EXAMINATION	NNP	I-NP	O
:	:	:	O	O
Notable	Notable	NNP	B-NP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
obese	obese	JJ	I-NP	O
pleasant	pleasant	NN	I-NP	O
woman	woman	NN	I-NP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
apparent	apparent	JJ	I-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

Temperature	Temperature	NN	B-NP	B-protein
99.3	99.3	CD	I-NP	I-protein
,	,	,	O	O
pulse	pulse	NN	B-NP	O
88	88	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
130/80	130/80	CD	I-NP	O
,	,	,	O	O
respirations	respiration	NNS	B-NP	O
20	20	CD	B-NP	O
.	.	.	O	O

HEENT	HEENT	NN	B-NP	B-protein
was	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
being	be	VBG	B-VP	O
anicteric	anicteric	JJ	B-ADJP	O
,	,	,	O	O
fundi	fundus	NNS	B-NP	O
were	be	VBD	B-VP	O
flat	flat	JJ	B-ADJP	O
,	,	,	O	O
no	no	DT	B-NP	O
adenopathy	adenopathy	NN	I-NP	O
,	,	,	O	O
JVD	JVD	NN	B-NP	B-protein
,	,	,	O	O
bruits	bruit	NNS	B-NP	O
or	or	CC	O	O
increased	increase	VBN	B-NP	O
thyroid	thyroid	NN	I-NP	O
.	.	.	O	O

Heart	Heart	NN	B-NP	O
with	with	IN	B-PP	O
II/VI	II/VI	NN	B-NP	O
systolic	systolic	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
left	left	JJ	B-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
.	.	.	O	O

Lungs	Lung	NNS	B-NP	O
were	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
.	.	.	O	O

No	No	DT	B-NP	O
CVA	CVA	NN	I-NP	O
tenderness	tenderness	NN	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
with	with	IN	B-PP	O
bowel	bowel	NN	B-NP	O
sounds	sound	VBZ	B-VP	O
present	present	JJ	B-ADJP	O
,	,	,	O	O
liver	liver	NN	B-NP	O
10	10	CD	I-NP	O
cm	cm	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
guarding	guarding	NN	I-NP	O
or	or	CC	I-NP	O
rebound	rebound	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
spleen	spleen	NN	I-NP	O
,	,	,	I-NP	O
mass	mass	NN	I-NP	O
or	or	CC	I-NP	O
kidneys	kidney	NNS	I-NP	O
palpable	palpable	JJ	B-ADJP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
non-tender	non-tender	JJ	B-ADJP	O
,	,	,	O	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
edema	edema	NN	I-NP	O
at	at	IN	B-PP	O
ankle	ankle	NN	B-NP	O
,	,	,	O	O
right	right	JJ	B-NP	O
ankle	ankle	NN	I-NP	O
more	more	JJR	B-ADJP	O
than	than	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
ankle	ankle	NN	I-NP	O
.	.	.	O	O

Neuro	Neuro	NN	B-NP	O
exam	exam	NN	I-NP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
white	white	JJ	B-NP	O
count	count	NN	I-NP	O
2.4	2.4	CD	I-NP	O
,	,	,	O	O
Hct	Hct	NN	B-NP	B-protein
21.7	21.7	CD	I-NP	I-protein
,	,	,	O	O
MCV	MCV	NN	B-NP	B-protein
91.8	91.8	CD	I-NP	I-protein
,	,	,	O	O
platelet	platelet	NN	B-NP	O
count	count	NN	I-NP	O
15	15	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
;	;	:	O	O
differential	differential	JJ	B-NP	O
was	be	VBD	B-VP	O
polys	poly	NNS	B-NP	O
7	7	CD	B-NP	O
,	,	,	O	O
bands	band	NNS	B-NP	B-protein
1	1	CD	I-NP	I-protein
,	,	,	O	O
lymphs	lymph	NNS	B-NP	O
92	92	CD	B-NP	O
.	.	.	O	O

SMA	SMA	NN	B-NP	B-protein
7	7	CD	I-NP	I-protein
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
was	be	VBD	B-VP	O
sodium	sodium	NN	B-NP	O
139	139	CD	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
3.8	3.8	CD	I-NP	O
,	,	,	O	O
bicarb	bicarb	NN	B-NP	O
22	22	CD	I-NP	O
,	,	,	O	O
glucose	glucose	NN	B-NP	O
82	82	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
10	10	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
0.9	0.9	CD	I-NP	O
with	with	IN	B-PP	O
anion	anion	NN	B-NP	B-protein
gap	gap	NN	I-NP	I-protein
10	10	CD	I-NP	I-protein
.	.	.	O	O

LFTs	LFT	NNS	B-NP	O
revealed	reveal	VBD	B-VP	O
OT	OT	NN	B-NP	B-protein
66	66	CD	I-NP	I-protein
,	,	,	O	O
PT	PT	NN	B-NP	B-cell_line
102	102	CD	I-NP	I-cell_line
,	,	,	O	O
LDH	LDH	NN	B-NP	B-protein
221	221	CD	I-NP	I-protein
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
111	111	CD	B-NP	O
,	,	,	O	O
bili	bili	SYM	B-NP	O
0.3	0.3	CD	I-NP	O
/	/	SYM	I-NP	O
0.2	0.2	CD	I-NP	O
,	,	,	O	O
calcium	calcium	NN	B-NP	O
8.5	8.5	CD	I-NP	O
.	.	.	O	O

Cholesterol	Cholesterol	NN	B-NP	B-protein
143	143	CD	I-NP	I-protein
,	,	,	O	O
triglyceride	triglyceride	NN	B-NP	O
113	113	CD	I-NP	O
.	.	.	O	O

HIV	HIV	NN	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

HPV	HPV	NN	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

HCV	HCV	NN	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Beta	Beta	SYM	O	O
HCG	HCG	NN	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
received	receive	VBD	B-VP	O
a	a	DT	B-NP	O
10	10	CD	I-NP	O
day	day	NN	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
ATGAM	ATGAM	NN	B-NP	B-protein
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
,	,	,	O	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
temperature	temperature	NN	B-NP	O
to	to	TO	B-PP	O
105	105	CD	B-NP	O
with	with	IN	B-PP	O
response	response	NN	B-NP	O
to	to	TO	B-PP	O
holding	hold	VBG	B-VP	O
ATGAM	ATGAM	NN	B-NP	B-protein
and	and	CC	O	O
starting	start	VBG	B-VP	O
hydrocortisone	hydrocortisone	NN	B-NP	O
and	and	CC	O	O
restarting	restart	VBG	B-VP	O
ATGAM	ATGAM	NN	B-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
without	without	IN	B-PP	O
symptoms	symptom	NNS	B-NP	O
until	until	IN	B-PP	O
day	day	NN	B-NP	O
nine	nine	CD	I-NP	O
of	of	IN	B-PP	O
ATGAM	ATGAM	NN	B-NP	B-protein
when	when	WRB	B-ADVP	O
a	a	DT	B-NP	O
rash	rash	NN	I-NP	O
became	become	VBD	B-VP	O
apparent	apparent	JJ	B-ADJP	O
starting	start	VBG	B-PP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
forearm	forearm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
rectangular	rectangular	JJ	I-NP	O
red	red	JJ	I-NP	O
erythematous	erythematous	JJ	I-NP	O
maculopapular	maculopapular	JJ	I-NP	O
patch	patch	NN	I-NP	O
which	which	WDT	B-NP	O
later	later	RB	B-ADVP	O
extended	extend	VBD	B-VP	O
over	over	IN	B-PP	O
her	her	PRP$	B-NP	O
entire	entire	JJ	I-NP	O
body	body	NN	I-NP	O
and	and	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
pruritic	pruritic	JJ	B-ADJP	O
.	.	.	O	O

No	No	DT	B-NP	O
involvement	involvement	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
orpharynx	orpharynx	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
respiratory	respiratory	JJ	I-NP	O
compromise	compromise	NN	I-NP	O
were	be	VBD	B-VP	O
ever	ever	RB	I-VP	O
noted	note	VBN	I-VP	O
.	.	.	O	O

This	This	DT	B-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
been	be	VBN	I-VP	O
partly	partly	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
either	either	CC	O	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
ATGAM	ATGAM	NN	I-NP	B-protein
being	be	VBG	B-VP	O
turned	turn	VBD	I-VP	O
up	up	RP	B-PRT	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
night	night	NN	I-NP	O
of	of	IN	B-PP	O
6	6	CD	B-NP	O
of	of	IN	B-PP	O
March	March	NNP	B-NP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
by	by	IN	B-PP	O
accident	accident	NN	B-NP	O
or	or	CC	O	O
also	also	RB	B-ADVP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
been	be	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
Ceftaz	Ceftaz	NNP	B-NP	O
and	and	CC	I-NP	O
Vanco	Vanco	NNP	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
6	6	CD	B-NP	O
of	of	IN	B-PP	O
March	March	NNP	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
febrile	febrile	JJ	I-NP	O
episode	episode	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
eighth	eighth	JJ	I-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
ATGAM	ATGAM	NN	B-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
fever	fever	NN	B-NP	O
to	to	TO	B-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
erythematous	erythematous	JJ	I-NP	O
eardrum	eardrum	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
couple	couple	NN	I-NP	O
of	of	IN	B-PP	O
posterior	posterior	JJ	B-NP	O
cervical	cervical	JJ	I-NP	O
nodes	node	NNS	I-NP	O
one	one	CD	B-NP	O
measuring	measure	VBG	B-VP	O
about	about	IN	B-NP	O
1	1	CD	I-NP	O
cm	cm	NN	I-NP	O
x	x	SYM	O	O
2	2	CD	B-NP	O
cm	cm	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
tender	tender	NN	B-NP	O
to	to	TO	B-PP	O
palpation	palpation	NN	B-NP	O
,	,	,	O	O
also	also	RB	B-ADVP	O
some	some	DT	B-NP	O
erythema	erythema	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
side	side	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
oropharynx	oropharynx	NN	I-NP	O
.	.	.	O	O

Strep	Strep	NN	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
Ceftaz	Ceftaz	NNP	B-NP	O
and	and	CC	I-NP	O
Vanc	Vanc	NNP	I-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
otitis	otitis	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
later	later	RB	I-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
Augmentin	Augmentin	NNP	B-NP	O
when	when	WRB	B-ADVP	O
rash	rash	NN	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
possibly	possibly	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
Ceftaz	Ceftaz	NN	B-NP	O
and	and	CC	O	O
then	then	RB	O	O
this	this	DT	B-NP	O
again	again	RB	I-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
later	later	RB	B-ADVP	O
to	to	TO	B-VP	O
po	po	VB	I-VP	O
Cipro	Cipro	NNP	B-NP	O
when	when	WRB	B-ADVP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
no	no	RB	B-ADJP	O
longer	longer	RBR	I-ADJP	O
neutropenic	neutropenic	JJ	I-ADJP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
resolving	resolve	VBG	I-VP	O
.	.	.	O	O

During	During	IN	B-PP	O
the	the	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
rash	rash	NN	I-NP	O
her	her	PRP$	B-NP	O
urine	urine	NN	I-NP	O
also	also	RB	B-ADVP	O
changed	change	VBD	B-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
dark	dark	JJ	I-NP	O
coke-colored	coke-colored	JJ	I-NP	O
urine	urine	NN	I-NP	O
which	which	WDT	B-NP	O
contained	contain	VBD	B-VP	O
red	red	JJ	B-NP	B-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
,	,	,	O	O
no	no	DT	B-NP	O
casts	cast	NNS	I-NP	O
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
serum	serum	NN	B-NP	O
sickness	sickness	NN	I-NP	O
and	and	CC	B-PP	O
so	so	IN	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
prednisone	prednisone	NN	I-NP	O
started	start	VBD	B-VP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
ATGAM	ATGAM	NN	I-NP	B-protein
so	so	IN	B-SBAR	O
that	that	IN	I-SBAR	O
she	she	PRP	B-NP	O
would	would	MD	B-VP	O
be	be	VB	I-VP	O
afebrile	afebrile	JJ	B-ADJP	O
and	and	CC	O	O
to	to	TO	B-VP	O
minimize	minimize	VB	I-VP	O
reaction	reaction	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
ATGAM	ATGAM	NN	I-NP	B-protein
to	to	TO	B-PP	O
IV	IV	CD	B-NP	O
Solu	Solu	NNP	I-NP	O
Medrol	Medrol	NNP	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
responded	respond	VBD	B-VP	O
well	well	RB	B-ADVP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
with	with	IN	B-PP	O
urine	urine	NN	B-NP	O
changing	change	VBG	B-VP	O
rapidly	rapidly	RB	B-ADVP	O
to	to	TO	B-VP	O
yellow	yellow	VB	I-VP	O
color	color	NN	B-NP	O
still	still	RB	B-ADVP	O
with	with	IN	B-PP	O
some	some	DT	B-NP	O
RBCs	RBC	NNS	I-NP	B-cell_type
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
16	16	CD	B-NP	O
mg	mg	NN	I-NP	O
prednisone	prednisone	NN	I-NP	O
po	po	NN	I-NP	O
bid	bid	NN	I-NP	O
and	and	CC	O	O
followed	follow	VBD	B-VP	O
up	up	RP	B-PRT	O
in	in	IN	B-PP	O
Hematology	Hematology	NNP	B-NP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
sure	sure	JJ	B-ADJP	O
the	the	DT	B-NP	O
rash	rash	NN	I-NP	O
continues	continue	VBZ	B-VP	O
to	to	TO	I-VP	O
fade	fade	VB	I-VP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
urine	urine	NN	I-NP	O
continues	continue	VBZ	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
.	.	.	O	O

During	During	IN	B-PP	O
hospitalization	hospitalization	NN	B-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
required	require	VBD	B-VP	O
periodic	periodic	JJ	B-NP	O
transfusions	transfusion	NNS	I-NP	O
for	for	IN	B-PP	O
platelets	platelet	NNS	B-NP	B-cell_type
and	and	CC	O	O
packed	pack	VBD	B-VP	O
red	red	JJ	B-NP	B-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
.	.	.	O	O

She	She	PRP	B-NP	O
tolerated	tolerate	VBD	B-VP	O
the	the	DT	B-NP	O
packed	packed	JJ	I-NP	O
red	red	JJ	I-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
transfusion	transfusion	NN	I-NP	O
well	well	RB	B-ADVP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
in	in	IN	B-PP	O
general	general	JJ	B-ADJP	O
she	she	PRP	B-NP	O
noted	note	VBD	B-VP	O
her	her	PRP$	B-NP	O
usual	usual	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
to	to	TO	B-PP	O
platelets	platelet	NNS	B-NP	B-cell_type
with	with	IN	B-PP	O
rigors	rigor	NNS	B-NP	O
and	and	CC	I-NP	O
chills	chill	NNS	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
hydrocortisone	hydrocortisone	NN	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
while	while	IN	B-SBAR	O
using	use	VBG	B-VP	O
Solu	Solu	NNP	B-NP	O
Medrol	Medrol	NNP	I-NP	O
one	one	CD	B-NP	O
night	night	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
one	one	CD	B-NP	O
bag	bag	NN	I-NP	O
of	of	IN	B-PP	O
platelets	platelet	NNS	B-NP	B-cell_type
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
little	little	JJ	I-NP	O
bit	bit	NN	I-NP	O
of	of	IN	B-PP	O
an	an	DT	B-NP	O
increased	increase	VBN	I-NP	O
rash	rash	NN	I-NP	O
which	which	WDT	B-NP	O
faded	fade	VBD	B-VP	O
rapidly	rapidly	RB	B-ADVP	O
on	on	IN	B-PP	O
stopping	stop	VBG	B-VP	O
the	the	DT	B-NP	O
platelets	platelet	NNS	I-NP	B-cell_type
and	and	CC	O	O
a	a	DT	B-NP	O
platelet	platelet	NN	I-NP	O
blood	blood	NN	I-NP	O
transfusion	transfusion	NN	I-NP	O
reaction	reaction	NN	I-NP	O
workup	workup	NN	I-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
labs	lab	NNS	I-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
are	be	VBP	B-VP	O
sodium	sodium	NN	B-NP	O
135	135	CD	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
4.8	4.8	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
20	20	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
1	1	CD	I-NP	O
,	,	,	O	O
LDH	LDH	NN	B-NP	B-protein
327	327	CD	I-NP	I-protein
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
263	263	CD	B-NP	O
,	,	,	O	O
magnesium	magnesium	NN	B-NP	O
2.1	2.1	CD	I-NP	O
,	,	,	O	O
calcium	calcium	NN	B-NP	O
9.4	9.4	CD	I-NP	O
,	,	,	O	O
white	white	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
2.4	2.4	CD	B-NP	O
with	with	IN	B-PP	O
36	36	CD	B-NP	O
polys	poly	NNS	I-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
band	band	NN	I-NP	O
,	,	,	O	O
55	55	CD	B-NP	O
lymphs	lymph	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
8	8	CD	B-NP	O
monos	mono	NNS	I-NP	O
,	,	,	O	O
Hct	Hct	NN	B-NP	B-protein
27.6	27.6	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
platelet	platelet	NN	B-NP	O
count	count	NN	I-NP	O
7000	7000	CD	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
one	one	CD	B-NP	O
bag	bag	NN	I-NP	O
of	of	IN	B-PP	O
platelets	platelet	NNS	B-NP	B-cell_type
,	,	,	O	O
MCV	MCV	NN	B-NP	O
88	88	CD	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Nystatin	Nystatin	NN	B-NP	O
5	5	CD	I-NP	O
cc	cc	NN	I-NP	O
po	po	NN	I-NP	O
qid	qid	NN	I-NP	O
prn	prn	NN	I-NP	O
,	,	,	O	O
60	60	CD	B-NP	O
mg	mg	NN	I-NP	O
prednisone	prednisone	NN	I-NP	O
po	po	NN	I-NP	O
bid	bid	NN	I-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
gm	gm	NN	I-NP	O
Carafate	Carafate	NN	I-NP	O
po	po	NN	I-NP	O
qid	qid	NN	I-NP	O
,	,	,	O	O
calcium	calcium	NN	B-NP	O
carbonate	carbonate	NN	I-NP	O
2500	2500	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	NN	I-NP	O
tid	tid	NN	I-NP	O
,	,	,	O	O
Ciprofloxacin	Ciprofloxacin	NN	B-NP	O
750	750	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	NN	I-NP	O
bid	bid	NN	I-NP	O
for	for	IN	B-PP	O
10	10	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
chlorhexadine	chlorhexadine	NN	B-NP	O
glucose	glucose	NN	I-NP	O
15	15	CD	I-NP	O
cc	cc	NN	I-NP	O
po	po	NN	I-NP	O
bid	bid	NN	I-NP	O
,	,	,	O	O
Benadryl	Benadryl	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	NN	I-NP	O
qid	qid	NN	I-NP	O
prn	prn	NN	I-NP	O
,	,	,	O	O
Monistat	Monistat	NN	B-NP	O
cream	cream	NN	I-NP	O
for	for	IN	B-PP	O
question	question	NN	B-NP	O
of	of	IN	B-PP	O
monoliasis	monoliasis	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Tylenol	Tylenol	NN	B-NP	O
prn	prn	NN	I-NP	O
.	.	.	O	O

Please	Please	NN	B-NP	B-protein
note	note	VBP	B-VP	O
that	that	IN	B-SBAR	O
prednisone	prednisone	NN	B-NP	O
dosage	dosage	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
in	in	IN	B-PP	O
Transfusion	Transfusion	NN	B-NP	O
Services	Service	NNS	I-NP	O
on	on	IN	B-PP	O
1	1	CD	B-NP	O
of	of	IN	B-PP	O
November	November	NNP	B-NP	O
as	as	IN	B-PP	O
per	per	IN	B-PP	O
need	need	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
stable	stable	JJ	B-ADJP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
return	return	VB	I-VP	O
to	to	TO	B-PP	O
Transfusion	Transfusion	NNP	B-NP	O
Service	Service	NNP	I-NP	O
on	on	IN	B-PP	O
1	1	CD	B-NP	O
of	of	IN	B-PP	O
November	November	NNP	B-NP	O
and	and	CC	O	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Tony	Tony	NNP	I-NP	O
Lowler	Lowler	NNP	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

________________________________	________________________________	LS	B-LST	O
VI657/0891	VI657/0891	NNP	B-NP	O
GREG	GREG	NNP	I-NP	O
D.	D.	NNP	I-NP	O
MCELRATH	MCELRATH	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
FO9	FO9	NNP	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
7/25/90	7/25/90	CD	B-NP	O
Batch	Batch	NNP	I-NP	O
:	:	:	O	O
1053	1053	CD	B-NP	O
Report	Report	NNP	I-NP	O
:	:	:	O	O
E8023F83	E8023F83	NN	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
10/15/90	10/15/90	CD	B-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
ZACKARY	ZACKARY	NNP	B-NP	O
PERRUZZA	PERRUZZA	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
cc	cc	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

PAULI	PAULI	NNP	B-NP	O
,	,	,	O	O
JR	JR	NNP	B-NP	O
,	,	,	O	O
COLIN	COLIN	NNP	B-NP	O
D	D	NNP	I-NP	O
.	.	.	O	O

